EUVIMEDEUVIMED entdecken
Crossref

Correlation analysis between driver gene mutation and clinicopathological features in lung adenocarcinoma

闫娜(Na Yan)

China National GeneBank DataBase · 01.01.2023

DOI: 10.26036/cnp0004402 ↗

Kurz gefasst

Fachartikel in der Zeitschrift China National GeneBank DataBase, erschienen am 01.01.2023. Verfasst von 闫娜(Na Yan).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Approximately 80% of lung cancer cases are classified as non-small cell lung cancer (NSCLC)1. The most common subtype of NSCLC is lung adenocarcinoma (LUAD), which accounts for approximately 55% of NSCLC2. LUAD has higher incidence and case fatality rates compared to other types of malignant tumors and exhibits a high level of genetic heterogeneity3. Despite significant improvements in clinical treatment through traditional surgery and the combination of radiotherapy and chemotherapy, overall efficacy and prognosis remain limited. In the past twenty years, with the development of tumor molecular biology and the gradual deepening of gene research, the diagnosis and treatment of LUAD have undergone significant changes4-7. The development and application of targeted drugs have extended survival and improved LUAD patients' quality of life8. The carcinogenic mutation of the epidermal growth factor receptor (EGFR) tyrosine kinase domain showed a significant clinical response to the first-generation EGFR tyrosine kinase inhibitor (TKI) gefitinib in 20044,9, ushering in the era of targeted treatment for NSCLC. Three years later, the discovery of ALK rearrangement broadened the scope of targeted genomic changes in the disease5,10. Subsequently, some other driving events with strong transformation potential were reported, including somatic oncogenic mutations of ROS1, RET, BRAF, gene insertion of HER2, and exon 14 skipping of MET proto-oncogene8,11. Driving genes are essential predictors of targeted therapeutic efficacy. Detecting driver gene mutations in LUAD patients can help screen for targeted drugs, improving patient survival benefits12-15. This study analyzed the mutations of driving genes (EGFR, KRAS, ALK, ROS1, RET, MET, BRAF, HER2, PIK3CA and NRAS) in LUAD and their correlation with clinical pathological features, providing a theoretical basis for promoting multi-gene joint detection.

Schlagwörter

lung adenocarcinomadriver mutationsclinicopathological featuresEGFRKRASALK rearrangementROS1RETMETBRAF

Zitieren

APA

Yan), 闫. (2023). Correlation analysis between driver gene mutation and clinicopathological features in lung adenocarcinoma. China National GeneBank DataBase. https://doi.org/10.26036/cnp0004402

Vancouver

Yan) 闫. Correlation analysis between driver gene mutation and clinicopathological features in lung adenocarcinoma. China National GeneBank DataBase. 2023. doi:10.26036/cnp0004402

BibTeX
@article{Yan2023,
  author = {Yan), 闫娜(Na},
  title = {Correlation analysis between driver gene mutation and clinicopathological features in lung adenocarcinoma},
  journal = {China National GeneBank DataBase},
  year = {2023},
  doi = {10.26036/cnp0004402}
}
Kostenlos starten →